ArticleJournal of biological engineering2026
Catalytic nanotherapeutics with cancer cell membrane and chitosan-coated Cu/Pt nanoparticles for gastric cancer precision therapy.
Article in Journal of biological engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Gastric cancer remains a major global health challenge, underscoring the need for highly effective and precisely targeted therapies. This study presents a novel biomimetic nanoplatform comprising cancer cell membrane-coated chitosan-stabilized Cu/Pt nanoparticles (CCM@Ch-Cu/PtNPs), designed to enhance tumor specificity and therapeutic efficacy. We characterized the nanocomposite using X-ray diffraction (XRD), X-ray absorption spectroscopy (XAS), and transmission electron microscopy (TEM), confirming its bimetallic architecture featuring Cu-rich and Pt-rich surface domains. In vitro, treatment with CCM@Ch-Cu/PtNPs (75 µg/mL) markedly decreased viability and colony formation in AGS and HGC gastric cancer cell lines, induced apoptosis, and triggered reactive oxygen species (ROS) generation, indicating potent cytotoxic activity and disruption of oncogenic pathways. In vivo, systemic administration of CCM@Ch-Cu/PtNPs in a murine gastric cancer model resulted in preferential tumor accumulation, substantial tumor growth inhibition, and prolonged survival, all achieved without detectable organ toxicity. These results support the potential of CCM@Ch-Cu/PtNPs as a theranostic nanomedicine platform for targeted gastric cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.